Q-omics provides the consensus-scored RBM42 profile across patient tissues and cancer cell-line models. RBM42 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RBM42 is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, RBM42 protein abundance shows 22,965 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, COAD, and LSCC as cancer lineages where RBM42 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RBM42 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RBM42 survival associations across molecular data types. RBM42 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RBM42 RNA expression–survival associations across cancer types. High RBM42 expression shows unfavorable associations in ACC, LGG, LUAD, PRAD and KIRC, but favorable associations in SCLC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RBM42 RNA expression.
This table summarizes RBM42 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in COAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for RBM42. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RBM42 shows higher tumor expression in COAD, HNSC, KIRP, LIHC, STAD and BLCA. The COAD box plot shows higher RBM42 RNA expression in tumor versus normal tissue (log2 FC = +0.573, t-test p < 0.001).
This table shows molecular features associated with RBM42 in patient tissues and cancer cell lines. In patient samples, RBM42 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, RBM42 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BLOOD_Lymphoma.
